1. Kargar S, Tabatabaei SM, Okati-Aliabad H, Rad HI. Prevalence of Thyroid Dysfunction Disorders among Adult Populations in the Middle-East: A Systematic Review and Meta-analysis. Open Public Health J. 2024;17(1). [
DOI:10.2174/0118749445317174240827052511]
2. Saleh DS, Othman MS. Exploring the challenges of diagnosing thyroid disease with imbalanced data and machine learning: A systematic literature review. Baghdad Sci J. 2024;21(3):1119-36. [
DOI:10.21123/bsj.2023.8544]
3. Mefford L. Disorders of endocrine control of growth and metabolism. Noris TL, ed Porth's Pathophysiology: Concepts of Altered Health States: Wolters Kluwer; 2025. p. 1235-80.
4. Somerall D, Somerall W. Thyroid disorders in women: evaluation, diagnosis, and management. Clin J Nurse Pract Women's Health. 2025;2(2):79-87. [
DOI:10.1891/CJNPWH-2512]
5. Abubakar MZ, Abdulsalam K, Yahaya IA. Thyroid hormones profile of patients with type 2 diabetes mellitus in Kano, Nigeria. Ann Afr Med. 2020;3(1). [
DOI:10.4081/aamr.2020.112]
6. Iedan MA, Al-Rubaei ZMM. Chitotriosidase-1 levels in Iraqi Type 2 Diabetic Patients with Thyroid Disorders. Ibn AL-Haitham J Pure App Sci. 2019;32(2):45-50. [
DOI:10.30526/32.2.2138]
7. Al-Odat I, Al-Fawaeir S, Al-Mahmoud MH. Study of the association between thyroid dysfunction and serum lipid abnormalities. Biomed Rep. 2024;21(4):138. [
DOI:10.3892/br.2024.1826] [
PMID] [
PMCID]
8. Abdollahi A, Nozarian Z, Salarvand S, Pourebrahimi E. The Link Between High Sensitivity Troponin T Levels and Outcomes Among Patients with Congestive Heart Failure: A Systematic Review and Meta-Analysis Study. Iran J Pathol. 2025;20(3):245-56. [
DOI:10.30699/ijp.2025.2057561.3440] [
PMID] [
PMCID]
9. Taşdemir E, Şermet A. The relationship between plasma adipsin, adiponectin, vaspin, visfatin, and leptin levels with glucose metabolism and diabetes parameters. diabetes. 2019;15:21. [
DOI:10.14744/hnhj.2019.62534]
10. Bajilan SI. Evaluation of Adipose Tissue Hormones and Tumor Necrosis Factor in Patients with Endometriosis. J Contemp Med Sci. 2024;10(5):340-5. [
DOI:10.22317/jcms.v10i5.1616]
11. Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, et al. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy. Invest Ophthalmol Vis Sci. 2023;64(11):13. [
DOI:10.1167/iovs.64.11.13] [
PMID] [
PMCID]
12. Duzenli FN, Yurtcu E, Keyif B, Basbug A. Unmasking metabolic clues: adipsin, irisin and osteopontin as biomarkers in polycystic ovary syndrome and their impact on metabolic dynamics: a case-control study. Ginekol Pol. 2025;96(7):532-41. [
DOI:10.5603/gpl.102676] [
PMID]
13. Gómez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med. 2019;25(11):1739-47. [
DOI:10.1038/s41591-019-0610-4] [
PMID] [
PMCID]
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. [
DOI:10.1093/clinchem/18.6.499] [
PMID]
15. Brewster S, Bartholomew J, Holt RIG, Price H. Non-attendance at diabetes outpatient appointments: a systematic review. Diabet Med. 2020;37(9):1427-42. [
DOI:10.1111/dme.14241] [
PMID]
16. Dawood A, Abed B, Farhan L, Salman I. Evaluation of Neudesin Level in A sample of Iraqi Patients with Hypothyroidism. Iraqi J Sci. 2024:6205-13. [
DOI:10.24996/ijs.2024.65.11.1]
17. Abass E, Al-Sa'adsi W, Moslem M. Retinol-binding protein-4 and progranulin in Iraqi women with thyroid disorder. Int J Drug Deliv Technol. 2021;11(1):36-41.
18. Mintziori G, Veneti S, Poppe K, Goulis DG, Armeni E, Erel CT, et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024;185:107991. [
DOI:10.1016/j.maturitas.2024.107991] [
PMID]
19. 19 Ayatollahi A, Moosavi Z, Ayatollahi H. Serum C-reactive Protein Levels About Insulin Resistance and Beta Cell Function in Iranian Women with Subclinical Hypothyroidism. Iran J Pathol, 2024;19(3):326-31. [
DOI:10.30699/ijp.2024.2015823.3213] [
PMID] [
PMCID]
20. Kalra S, Aggarwal S, Khandelwal D. Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management. Diabetes Ther. 2019;10(6):2035-44. [
DOI:10.1007/s13300-019-00700-4] [
PMID] [
PMCID]
21. Salman Jasim H, Khalid Shafeeq N, Abass EAA. Vitamin D Level and its Relation with the Newly Diagnosed Diabetic Neuropathy in Women with Hypothyroidism. Arch Razi Inst. 2022;77(3):1139-45.
22. Al-Rubaei ZM, Abdulhadi GH, Alrubaye IM, Alrugaibi AH. Comparative study of fetuin-a levels l Iraqi diabetic patients with hyper and thyroid disorder. Biochem Cell Arch. 2021;21(1):53-7.
23. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011;2011:439463. [
DOI:10.4061/2011/439463] [
PMID] [
PMCID]
24. Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schön MR, et al. Adipsin Serum Concentrations and Adipose Tissue Expression in People with Obesity and Type 2 Diabetes. Int J Mol Sci. 2022;23(4):2222. [
DOI:10.3390/ijms23042222] [
PMID] [
PMCID]
25. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41-53. [
DOI:10.1016/j.cell.2014.06.005] [
PMID] [
PMCID]
26. Farhan LO, Abed BA, Dawood A. Comparison study between adipsin levels in sera of Iraqi patients with diabetes and neuropathy. Baghdad Sci J. 2023;20(3):726-33. [
DOI:10.21123/bsj.2022.7408]
27. Dare A, Chen SY. Adipsin in the pathogenesis of cardiovascular diseases. Vascul Pharmacol. 2024;154:107270. [
DOI:10.1016/j.vph.2023.107270] [
PMID] [
PMCID]
28. Raoof EM, Ahmed HS. Circulating adipsin as biomarker and its implication in type 2 diabetes mellitus. Int J Drug Deliv Technol. 2022;12(2):588-93.
29. Jawzal K, Hami M, Mohammed L, Ibrahiem A. The relationship between thyroid hormones and lipid profile in subclinical hypothyroidism female patients. Baghdad J Biochem Appl Biol Sci. 2022;3(03):200-9. [
DOI:10.47419/bjbabs.v3i03.137]
30. Maleki N, Kazerouni F, Hedayati M, Rahimipour A, Maleki H. Assessment of cardiovascular risk factors in patients with subclinical hypothyroidism. Acta Cardiol. 2016;71(6):691-7. [
DOI:10.1080/AC.71.6.3178188] [
PMID]
31. Karthick N, Dillara K, Poornima KN, Subhasini AS. Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res. 2013;7(10):2122. [
DOI:10.7860/JCDR/2013/5777.3448] [
PMID] [
PMCID]
32. Neves C, Alves M, Medina JL, Delgado JL. Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol. 2008;27(10):1211-36.
33. Jouad HA. Atherogenic indications in thyroidism patients and risk of cardiovascular diseases. Iraqi J Mark Res Consum Prot. 2023;15(2):74-82. [
DOI:10.28936/jmracpc15.2.2023.(8)]